{"id":"NCT00348283","sponsor":"Abbott","briefTitle":"Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab Endoscopy Trial to Evaluate the Effects on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-08","primaryCompletion":"2008-09","completion":null,"firstPosted":"2006-07-04","resultsPosted":"2010-02-11","lastUpdate":"2011-04-11"},"enrollment":135,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"BIOLOGICAL","name":"adalimumab","otherNames":["ABT-D2E7","Humira"]},{"type":"BIOLOGICAL","name":"placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"adalimumab","otherNames":["ABT-D2E7","Humira"]}],"arms":[{"label":"Double Blind","type":"PLACEBO_COMPARATOR"},{"label":"Open Label","type":"OTHER"}],"summary":"The goal of this study was to test whether adalimumab can induce mucosal healing in subjects with moderate to severe ileocolonic Crohn's Disease.","primaryOutcome":{"measure":"Number of Subjects Without Mucosal Ulceration at Week 12","timeFrame":"Week 12","effectByArm":[{"arm":"Placebo","deltaMin":8,"sd":null},{"arm":"Adalimumab","deltaMin":17,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.056"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":14},"locations":{"siteCount":21,"countries":["United States","Austria","Belgium","Canada","France","Germany","Italy","Netherlands"]},"refs":{"pmids":["34546360","29380251","26234693","23856361"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":0},"commonTop":["Crohn's disease","Nasopharyngitis","Headache","Abdominal pain","Arthralgia"]}}